| Cervical carcinoma: a comparison of four potential biochemical tumor markers. | |
| | |
MedLine Citation:
|
PMID: 2910788 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A longitudinal study of circulating immune complexes (CIC), cancer antigen 125 (CA125), carcinoembryonic antigen (CEA) and a sub-fraction of the TA-4 squamous cell carcinoma tumor-associated antigen (SCC) has been undertaken in 38 patients with cervical carcinoma. Pre- and post-treatment values have been compared with those obtained in well-defined clinical remission and relapse phases of their disease. Each tumor marker was assessed in terms of "lead time" before clinically obvious recurrent disease became evident. The data from the four subjects with adenocarcinoma of the cervix gave equivocal results and no firm conclusions could be drawn. However, for the 34 patients with squamous cell carcinoma the medium value (data was skewed) for SCC was elevated above normal in the presenting pretreatment sera (4.5 ng/ml) and significantly fell to 2.5 ng/ml post-treatment (P less than 0.01). A similar pattern was not apparent for CIC, CEA, or CA125 data. When results were examined for an individual patient, of those with recurrent squamous cell lesions who died, 12/24 demonstrated elevated, and rising SCC values before clinical evidence of the disease and a further 6 (25%) at the time recurrence was clinically evident. This information gave lead times of between 2 and 52 months (median 13 months) for 75% of patients. Only 1 subject had values which remained in the normal range (less than 2 ng/ml) even though their disease was progressive. Similarly of the subjects still in clinical remission 8/9 had values within the normal range. The data for CIC, CA125, and CEA were not individually useful as a marker. Furthermore, combining the data from all analytes to give a panel of potential markers did not improve the prognosis already evident with SCC alone. It has therefore been concluded that SCC is a useful biochemical marker of the progression of squamous cell carcinoma of the cervix. |
| | |
Authors:
|
J K Dodd; R J Henry; J P Tyler; C R Houghton |
Related Documents
:
|
20686378 - Clinical significance of serum ca-125 and soluble tumor necrosis factor receptor type i... 17418898 - Plasma activity of thrombin activatable fibrinolysis inhibitor in crimean-congo hemorrh... 17449138 - Serum tumor markers as predictors for survival in advanced non-small cell lung cancer p... 12499778 - Low levels of endostatin in the urine from patients with malignant disease. 8523308 - Thyroid malignancy in multinodular goitre and solitary nodule. 7260868 - Management and survival of female patients with "minimal" breast cancer: as observed in... |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Gynecologic oncology Volume: 32 ISSN: 0090-8258 ISO Abbreviation: Gynecol. Oncol. Publication Date: 1989 Feb |
Date Detail:
|
Created Date: 1989-02-23 Completed Date: 1989-02-23 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0365304 Medline TA: Gynecol Oncol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 248-52 Citation Subset: IM |
Affiliation:
|
Department of Obstetrics and Gynaecology, University of Sydney, Westmead Hospital, N.S.W., Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
blood*,
diagnosis Antigen-Antibody Complex / analysis Antigens, Neoplasm / analysis Antigens, Tumor-Associated, Carbohydrate / analysis Carcinoembryonic Antigen / analysis Carcinoma, Squamous Cell / blood*, diagnosis Female Humans Serpins* Tumor Markers, Biological / blood* Uterine Cervical Neoplasms / blood*, diagnosis |
| Chemical | |
Reg. No./Substance:
|
0/Antigen-Antibody Complex; 0/Antigens, Neoplasm; 0/Antigens, Tumor-Associated, Carbohydrate; 0/Carcinoembryonic Antigen; 0/Serpins; 0/Tumor Markers, Biological; 0/squamous cell carcinoma-related antigen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Second-look procedures in ovarian cancer patients receiving six vs. nine courses of platinum, adriam...
Next Document: Pulmonary lymphangitic carcinomatosis secondary to cervical carcinoma: a case report.